{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(11)"],"submitter":["Puechal X"],"pubmed_abstract":["<h4>Importance</h4>Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.<h4>Objective</h4>To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients.<h4>Design, setting, and participants</h4>This comparative effectiveness study used multicenter target trial emulation observational data from 32 French hospi"],"journal":["JAMA network open"],"pagination":["e2243799"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9706346"],"repository":["biostudies-literature"],"pubmed_title":["Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis."],"pmcid":["PMC9706346"],"pubmed_authors":["Neel A","Rossert J","Vinzio S","Merrien D","Puechal X","Bezanahary H","Porcher R","Thervet E","Quemeneur T","Mouthon L","Regent A","Ayach B","Graffin B","Jebrak G","Bonnotte B","Gondran G","Perrodeau E","Desmurs-Clavel H","Le Jeunne C","Michel M","Le Gallou T","Achard-Hottelart C","Colin T","Karras A","Olivier Y","Limal N","Marie I","Dion JJ","Pasqualoni E","Blanchard-Delaunay C","Delbrel X","Legallicier B","Terrier B","Imbert B","Hamidou M","Ruivard M","Lifermann F","Cohen P","Grassin F","Guillevin L","Diot E","French Vasculitis Study Group","Iudici M","Cottin V","Loustaud-Ratti V","de Lacroix-Szmania I","Hanrotel-Saliou C","Charasse C","Boffa JJ","Godeau B","Aumaitre O","Aouba A","Ravaud P","Le Hello C"],"additional_accession":[]},"is_claimable":false,"name":"Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.","description":"<h4>Importance</h4>Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.<h4>Objective</h4>To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients.<h4>Design, setting, and participants</h4>This comparative effectiveness study used multicenter target trial emulation observational data from 32 French hospi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-29T11:09:56.007Z","creation":"2025-04-06T19:49:38.3Z"},"accession":"S-EPMC9706346","cross_references":{"pubmed":["36441554"],"doi":["10.1001/jamanetworkopen.2022.43799"]}}